Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:01:37 UTC
Update Date2021-09-14 15:39:00 UTC
HMDB IDHMDB0014256
Secondary Accession Numbers
  • HMDB14256
Metabolite Identification
Common NameTafluprost free acid
DescriptionTafluprost free acid belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. Based on a literature review a small amount of articles have been published on Tafluprost free acid.
Structure
Data?1582753163
Synonyms
ValueSource
(5Z)-7-{2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoateHMDB
Chemical FormulaC22H28F2O5
Average Molecular Weight410.4515
Monoisotopic Molecular Weight410.190480416
IUPAC Name(5Z)-7-{2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoic acid
Traditional Name(5Z)-7-{2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoic acid
CAS Registry NumberNot Available
SMILES
OC1CC(O)C(\C=C\C(F)(F)COC2=CC=CC=C2)C1C\C=C/CCCC(O)=O
InChI Identifier
InChI=1S/C22H28F2O5/c23-22(24,15-29-16-8-4-3-5-9-16)13-12-18-17(19(25)14-20(18)26)10-6-1-2-7-11-21(27)28/h1,3-6,8-9,12-13,17-20,25-26H,2,7,10-11,14-15H2,(H,27,28)/b6-1-,13-12+
InChI KeyKIQXRQVVYTYYAZ-MTNCBHNASA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Long-chain fatty acid
  • Phenoxy compound
  • Phenol ether
  • Alkyl aryl ether
  • Halogenated fatty acid
  • Hydroxy fatty acid
  • Monocyclic benzene moiety
  • Fatty acid
  • Benzenoid
  • Unsaturated fatty acid
  • Cyclopentanol
  • Cyclic alcohol
  • Secondary alcohol
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Organohalogen compound
  • Organofluoride
  • Organooxygen compound
  • Alcohol
  • Hydrocarbon derivative
  • Carbonyl group
  • Organic oxide
  • Alkyl halide
  • Alkyl fluoride
  • Organic oxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Ontology
Not AvailableNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.034 g/LALOGPS
logP3.42ALOGPS
logP3.37ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)4.36ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 ŲChemAxon
Rotatable Bond Count11ChemAxon
Refractivity106.65 m³·mol⁻¹ChemAxon
Polarizability42 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+197.47530932474
DeepCCS[M-H]-194.87530932474
DeepCCS[M-2H]-229.40830932474
DeepCCS[M+Na]+204.63630932474
AllCCS[M+H]+198.832859911
AllCCS[M+H-H2O]+196.332859911
AllCCS[M+NH4]+201.032859911
AllCCS[M+Na]+201.632859911
AllCCS[M-H]-196.332859911
AllCCS[M+Na-2H]-197.432859911
AllCCS[M+HCOO]-198.832859911

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022.7.04 minutes32390414
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022.6.59 minutes32390414
Predicted by Siyang on May 30, 202213.6012 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20221.39 minutes32390414
Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid2629.0 seconds40023050
Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid226.2 seconds40023050
Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid187.4 seconds40023050
Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid190.6 seconds40023050
RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid199.0 seconds40023050
Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid602.1 seconds40023050
BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid505.2 seconds40023050
HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate)132.3 seconds40023050
UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid1246.6 seconds40023050
BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid536.2 seconds40023050
UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid1298.6 seconds40023050
SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid387.1 seconds40023050
RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid409.1 seconds40023050
MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate316.4 seconds40023050
KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA215.9 seconds40023050
Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water9.1 seconds40023050

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
Tafluprost free acidOC1CC(O)C(\C=C\C(F)(F)COC2=CC=CC=C2)C1C\C=C/CCCC(O)=O4130.2Standard polar33892256
Tafluprost free acidOC1CC(O)C(\C=C\C(F)(F)COC2=CC=CC=C2)C1C\C=C/CCCC(O)=O2890.4Standard non polar33892256
Tafluprost free acidOC1CC(O)C(\C=C\C(F)(F)COC2=CC=CC=C2)C1C\C=C/CCCC(O)=O2960.6Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Tafluprost free acid,1TMS,isomer #1C[Si](C)(C)OC1CC(O)C(/C=C/C(F)(F)COC2=CC=CC=C2)C1C/C=C\CCCC(=O)O2946.5Semi standard non polar33892256
Tafluprost free acid,1TMS,isomer #2C[Si](C)(C)OC1CC(O)C(C/C=C\CCCC(=O)O)C1/C=C/C(F)(F)COC1=CC=CC=C12938.1Semi standard non polar33892256
Tafluprost free acid,1TMS,isomer #3C[Si](C)(C)OC(=O)CCC/C=C\CC1C(O)CC(O)C1/C=C/C(F)(F)COC1=CC=CC=C12939.9Semi standard non polar33892256
Tafluprost free acid,2TMS,isomer #1C[Si](C)(C)OC1CC(O[Si](C)(C)C)C(C/C=C\CCCC(=O)O)C1/C=C/C(F)(F)COC1=CC=CC=C12921.5Semi standard non polar33892256
Tafluprost free acid,2TMS,isomer #2C[Si](C)(C)OC(=O)CCC/C=C\CC1C(O[Si](C)(C)C)CC(O)C1/C=C/C(F)(F)COC1=CC=CC=C12888.1Semi standard non polar33892256
Tafluprost free acid,2TMS,isomer #3C[Si](C)(C)OC(=O)CCC/C=C\CC1C(O)CC(O[Si](C)(C)C)C1/C=C/C(F)(F)COC1=CC=CC=C12879.4Semi standard non polar33892256
Tafluprost free acid,3TMS,isomer #1C[Si](C)(C)OC(=O)CCC/C=C\CC1C(O[Si](C)(C)C)CC(O[Si](C)(C)C)C1/C=C/C(F)(F)COC1=CC=CC=C12837.7Semi standard non polar33892256
Tafluprost free acid,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1CC(O)C(/C=C/C(F)(F)COC2=CC=CC=C2)C1C/C=C\CCCC(=O)O3181.3Semi standard non polar33892256
Tafluprost free acid,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC1CC(O)C(C/C=C\CCCC(=O)O)C1/C=C/C(F)(F)COC1=CC=CC=C13169.3Semi standard non polar33892256
Tafluprost free acid,1TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)CCC/C=C\CC1C(O)CC(O)C1/C=C/C(F)(F)COC1=CC=CC=C13197.2Semi standard non polar33892256
Tafluprost free acid,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1CC(O[Si](C)(C)C(C)(C)C)C(C/C=C\CCCC(=O)O)C1/C=C/C(F)(F)COC1=CC=CC=C13339.4Semi standard non polar33892256
Tafluprost free acid,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC(=O)CCC/C=C\CC1C(O[Si](C)(C)C(C)(C)C)CC(O)C1/C=C/C(F)(F)COC1=CC=CC=C13339.8Semi standard non polar33892256
Tafluprost free acid,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)CCC/C=C\CC1C(O)CC(O[Si](C)(C)C(C)(C)C)C1/C=C/C(F)(F)COC1=CC=CC=C13332.9Semi standard non polar33892256
Tafluprost free acid,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)CCC/C=C\CC1C(O[Si](C)(C)C(C)(C)C)CC(O[Si](C)(C)C(C)(C)C)C1/C=C/C(F)(F)COC1=CC=CC=C13470.7Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Tafluprost free acid GC-MS (Non-derivatized) - 70eV, Positivesplash10-014r-1219000000-8e1ec65ae01361e172d12017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Tafluprost free acid GC-MS (3 TMS) - 70eV, Positivesplash10-03di-5500489000-95bafbabe02fb2fdaf572017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Tafluprost free acid GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 10V, Positive-QTOFsplash10-002g-1029100000-204ed18144108c4fbbb22016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 20V, Positive-QTOFsplash10-002e-1229000000-25077f9e4ce508bf95e32016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 40V, Positive-QTOFsplash10-000b-9260000000-076c2111abf02e5ae67b2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 10V, Negative-QTOFsplash10-0006-9002200000-c00792117fdb4db5e3ef2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 20V, Negative-QTOFsplash10-0006-9001000000-08fd3ce154d6769f52222016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 40V, Negative-QTOFsplash10-0006-9110000000-0e95f48713dae3d602412016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 10V, Negative-QTOFsplash10-0006-9001300000-7aec5b4ddcff3ac3f0c22021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 20V, Negative-QTOFsplash10-0006-9000000000-08485aaf085c13d5129a2021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 40V, Negative-QTOFsplash10-0006-9000000000-08485aaf085c13d5129a2021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 10V, Positive-QTOFsplash10-004l-0049100000-6ef9a55a21ae3bd86e512021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 20V, Positive-QTOFsplash10-00nr-2289000000-5abc56977aad023ef4d02021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tafluprost free acid 40V, Positive-QTOFsplash10-00pu-9232000000-28994a5f3f961fcc7dbc2021-09-25Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Extracellular
Biospecimen Locations
  • Blood
  • Urine
Tissue Locations
  • Kidney
  • Liver
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID21467507
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound131750728
PDB IDNot Available
ChEBI ID176015
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
  2. Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
  3. Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
  4. Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
  5. Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.

Enzymes

General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum
Gene Name:
PTGFR
Uniprot ID:
P43088
Molecular weight:
40054.1
References
  1. Pantcheva MB, Seibold LK, Awadallah NS, Kahook MY: Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Ther. 2011 Sep;28(9):707-15. doi: 10.1007/s12325-011-0055-8. Epub 2011 Aug 18. [PubMed:21858491 ]